N NUVATION BIO INC
| Market Cap | $1.53B |
| P/E Ratio | — |
| Forward P/E | -30.41 |
| Dividend Yield | — |
| Beta | 1.61 |
| 52W Range | $1.66 - $9.54 |
| # Hedge Funds | 3 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 2 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| David Abrams Abrams Capital Management | 0.60% | $34.15M | 3,811,513 | — |
| David Einhorn DME Capital Management | 0.01% | $313.00K | 34,995 | Buy |
Insider Trading
| Insider Name of the company insider who made the trade 20 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Liu DongfangCHIEF MEDICAL OFFICER | Sale | 150,000 | $7.82 | $1.17M | 01 Dec 2025 | 03 Dec 2025 |
| Dongfang LiuCHIEF MEDICAL OFFICER | Sale | 150,000 | $7.82 | $1.17M | 01 Dec 2025 | 03 Dec 2025 |
| Liu DongfangCHIEF MEDICAL OFFICER | Sale | 10,000 | $8.00 | $80.00K | 26 Nov 2025 | 26 Nov 2025 |
| Dongfang LiuCHIEF MEDICAL OFFICER | Sale | 10,000 | $8.00 | $80.00K | 26 Nov 2025 | 26 Nov 2025 |
| Liu DongfangCHIEF MEDICAL OFFICER | Sale | 10,000 | $7.50 | $75.00K | 25 Nov 2025 | 26 Nov 2025 |
| Dongfang LiuCHIEF MEDICAL OFFICER | Sale | 10,000 | $7.50 | $75.00K | 25 Nov 2025 | 26 Nov 2025 |
| Hattersley GaryCHIEF SCIENTIFIC OFFICER | Sale | 300,000 | $7.23 | $2.17M | 20 Nov 2025 | 24 Nov 2025 |
| Liu DongfangCHIEF MEDICAL OFFICER | Sale | 20,000 | $7.00 | $140.07K | 20 Nov 2025 | 24 Nov 2025 |
| Hattersley GaryCHIEF SCIENTIFIC OFFICER | Sale | 69,051 | $7.23 | $499.03K | 20 Nov 2025 | 24 Nov 2025 |
| Dongfang LiuCHIEF MEDICAL OFFICER | Sale | 20,000 | $7.00 | $140.07K | 20 Nov 2025 | 24 Nov 2025 |
| Gary HattersleyCHIEF SCIENTIFIC OFFICER | Sale | 300,000 | $7.23 | $2.17M | 20 Nov 2025 | 24 Nov 2025 |
| Gary HattersleyCHIEF SCIENTIFIC OFFICER | Sale | 69,051 | $7.23 | $499.03K | 20 Nov 2025 | 24 Nov 2025 |
| Hanley David C.CHIEF TECHNICAL OPERATIONS | Sale | 200,000 | $7.14 | $1.43M | 19 Nov 2025 | 21 Nov 2025 |
| Liu DongfangCHIEF MEDICAL OFFICER | Sale | 15,000 | $5.10 | $76.55K | 19 Nov 2025 | 19 Nov 2025 |
| David C. HanleyCHIEF TECHNICAL OPERATIONS | Sale | 200,000 | $7.14 | $1.43M | 19 Nov 2025 | 21 Nov 2025 |
| Dongfang LiuCHIEF MEDICAL OFFICER | Sale | 15,000 | $5.10 | $76.55K | 19 Nov 2025 | 19 Nov 2025 |
| Liu DongfangCHIEF MEDICAL OFFICER | Sale | 15,000 | $4.77 | $71.47K | 17 Nov 2025 | 19 Nov 2025 |
| Dongfang LiuCHIEF MEDICAL OFFICER | Sale | 15,000 | $4.77 | $71.47K | 17 Nov 2025 | 19 Nov 2025 |
| Hattersley GaryCHIEF SCIENTIFIC OFFICER | Sale | 100,000 | $5.02 | $502.46K | 27 Oct 2025 | 29 Oct 2025 |
| Gary HattersleyCHIEF SCIENTIFIC OFFICER | Sale | 100,000 | $5.02 | $502.46K | 27 Oct 2025 | 29 Oct 2025 |
Frequently Asked Questions
What is NUVB stock price today?
NUVATION BIO INC (NUVB) is currently trading at $4.41. The stock has a 52-week range of $1.66 to $9.54 and a market capitalization of $1.53B.
Is NUVB a good stock to buy in 2026?
NUVATION BIO INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +165.7%. 2 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling NUVB stock?
There have been 20 insider transactions for NUVB in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has NUVB stock performed over the past year?
NUVATION BIO INC (NUVB) has returned +165.7% over the past 12 months. The stock traded between $1.66 and $9.54 during this period, and is currently at $4.41.
Which hedge funds own NUVB (NUVATION BIO INC)?
2 tracked hedge funds currently hold NUVB in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is NUVB's market cap and valuation?
NUVATION BIO INC (NUVB) has a market capitalization of $1.53B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is NUVB's revenue and profitability?
NUVATION BIO INC reported revenue of $62.90M with net income of N/A and a profit margin of N/A. The stock has a beta of 1.61.
What sector is NUVB in and who are its biggest institutional holders?
NUVATION BIO INC (NUVB) operates in the Healthcare sector. It is held by 2 tracked hedge funds. See the ownership table above for the complete list.